R Marcus

Summary

Affiliation: Addenbrooke's Hospital
Country: UK

Publications

  1. ncbi Current treatment options in aggressive lymphoma
    Robert Marcus
    Consultant Haematologist, Addenbrooke s Hospital, Cambridge, CB2 2QQ, UK
    Leuk Lymphoma 44:S15-27. 2003
  2. ncbi Pathogenesis of MALT lymphoma: implications for risk stratification and therapy
    Robert Marcus
    Department of Haematology, Addenbrookes Hospital, Cambridge, UK
    Leuk Lymphoma 48:2087-8. 2007
  3. ncbi CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
    Robert Marcus
    Dept of Haematology, Addenbrookes Hospital, Cambridge CB2 2QQ, UK
    Blood 105:1417-23. 2005
  4. pmc Should you tell patients about beneficial treatments that they cannot have? Yes
    Robert Marcus
    Addenbrooke s Hospital, Cambridge CB2 2QQ
    BMJ 334:826. 2007
  5. ncbi Use of rituximab in patients with follicular lymphoma
    R Marcus
    Department of Haematology, Addenbrookes Hospital, Cambridge, UK
    Clin Oncol (R Coll Radiol) 19:38-49. 2007
  6. pmc A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma
    R Marcus
    Department of Haematology, Kings College Hospital, London, UK
    Br J Cancer 102:19-22. 2010
  7. doi Intermediate dose gemcitabine-cisplatin combination chemotherapy without treatment delay for cytopenia followed by autografting--a new standard of care in relapsed or refractory Hodgkin lymphoma?
    T Todd
    Department of Haematology, Addenbrooke s Hospital, Cambridge, UK
    Ann Hematol 88:1107-12. 2009
  8. doi Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma
    Robert Marcus
    Department of Haematology, Addenbrooke s Hospital, Cambridge, UK
    J Clin Oncol 26:4579-86. 2008
  9. ncbi A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in
    G Jackson
    Department of Haematology, Royal Victoria Infirmary, Newcastle upon Tyne, UK
    Br J Haematol 112:127-37. 2001
  10. ncbi Monoclonal antibody therapy for lymphoma
    Peter Campbell
    Cambridge Institute of Medical Research, Hills Road, CB2 2XY, Cambridge, UK
    Blood Rev 17:143-52. 2003

Collaborators

Detail Information

Publications20

  1. ncbi Current treatment options in aggressive lymphoma
    Robert Marcus
    Consultant Haematologist, Addenbrooke s Hospital, Cambridge, CB2 2QQ, UK
    Leuk Lymphoma 44:S15-27. 2003
    ..The impact of these approaches on the treatment of diffuse, large B-cell lymphoma and mantle cell lymphoma is discussed below...
  2. ncbi Pathogenesis of MALT lymphoma: implications for risk stratification and therapy
    Robert Marcus
    Department of Haematology, Addenbrookes Hospital, Cambridge, UK
    Leuk Lymphoma 48:2087-8. 2007
  3. ncbi CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
    Robert Marcus
    Dept of Haematology, Addenbrookes Hospital, Cambridge CB2 2QQ, UK
    Blood 105:1417-23. 2005
    ..The addition of rituximab to the CVP regimen significantly improves the clinical outcome in patients with previously untreated advanced follicular lymphoma, without increased toxicity...
  4. pmc Should you tell patients about beneficial treatments that they cannot have? Yes
    Robert Marcus
    Addenbrooke s Hospital, Cambridge CB2 2QQ
    BMJ 334:826. 2007
  5. ncbi Use of rituximab in patients with follicular lymphoma
    R Marcus
    Department of Haematology, Addenbrookes Hospital, Cambridge, UK
    Clin Oncol (R Coll Radiol) 19:38-49. 2007
    ..This overview considers the most recently published clinical trials of rituximab and their potential effect on clinical practice in the treatment of follicular NHL...
  6. pmc A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma
    R Marcus
    Department of Haematology, Kings College Hospital, London, UK
    Br J Cancer 102:19-22. 2010
    ..To evaluate the impact of treatment on health states that affect patients' quality of life in advanced follicular lymphoma...
  7. doi Intermediate dose gemcitabine-cisplatin combination chemotherapy without treatment delay for cytopenia followed by autografting--a new standard of care in relapsed or refractory Hodgkin lymphoma?
    T Todd
    Department of Haematology, Addenbrooke s Hospital, Cambridge, UK
    Ann Hematol 88:1107-12. 2009
    ....
  8. doi Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma
    Robert Marcus
    Department of Haematology, Addenbrooke s Hospital, Cambridge, UK
    J Clin Oncol 26:4579-86. 2008
    ....
  9. ncbi A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in
    G Jackson
    Department of Haematology, Royal Victoria Infirmary, Newcastle upon Tyne, UK
    Br J Haematol 112:127-37. 2001
    ..It is therefore an important advance in developing new treatment options for these patients...
  10. ncbi Monoclonal antibody therapy for lymphoma
    Peter Campbell
    Cambridge Institute of Medical Research, Hills Road, CB2 2XY, Cambridge, UK
    Blood Rev 17:143-52. 2003
    ..Newer agents, including radiolabelled antibodies, immunotoxin-linked antibodies and antibodies against novel target antigens are showing promise in phase I and II trials in a variety of clinical settings...
  11. doi Treatment of oral mucositis after peripheral blood SCT with ATL-104 mouthwash: results from a randomized, double-blind, placebo-controlled trial
    A Hunter
    Department of Haematology, Leicester Royal Infirmary, Leicester, UK
    Bone Marrow Transplant 43:563-9. 2009
    ..Similar results were obtained using the WCCNR Scale. Adverse events (AEs) were predominantly mild or moderate in intensity. Gastrointestinal AE were most common...
  12. ncbi Distinguishing between entities--rationally based advances in the therapy of follicular lymphoma
    Robert Marcus
    Addenbrookes NHS Trust, Cambridge, UK
    Leuk Lymphoma 48:2285-6. 2007
  13. ncbi Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma
    Robert Marcus
    Addenbrooke s Hospital, Cambridge, UK
    Semin Oncol 32:S36-43. 2005
    ....
  14. ncbi Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma
    Anton Hagenbeek
    European Organisation for Research and Treatment of Cancer EORTC Lymphoma Group, Amsterdam, The Netherlands
    J Clin Oncol 24:1590-6. 2006
    ....
  15. ncbi Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study
    Cynthia S Kretschmar
    Boston Floating Hospital for Infants and Children, Department of Pediatrics, Division of Pediatric Oncology, 750 Washington St, Box 14, Boston, MA 02111, USA
    J Clin Oncol 22:4119-26. 2004
    ..The Pediatric Oncology Group conducted a study of paclitaxel, topotecan, and topotecan-cyclophosphamide (topo-cyclo) in newly diagnosed children with stage IV NB...
  16. ncbi Emerging treatments for indolent lymphoma
    Bruce D Cheson
    Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC 20057, USA
    Clin Adv Hematol Oncol 5:1-9; quiz 11-2. 2007
    ..Other emerging therapeutics include new chemotherapeutics, small-molecule and monoclonal antibodies, radioimmunotherapy, apoptosis-inducing agents, and immunomodulators...
  17. ncbi Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study
    Alberto S Pappo
    The Hospital for Sick Children, 555 University Ave, Toronto, ON, M5G1X8, Canada
    J Clin Oncol 23:4031-8. 2005
    ..To describe the response rate and survival of children and adolescents with unresected or metastatic nonrhabdomyosarcomatous soft tissue sarcomas (NRSTS) treated with vincristine, ifosfamide, and doxorubicin...
  18. ncbi Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation
    Franck Morschhauser
    Department of Hematology, Centre Hospitalier Universitaire, Lille, France
    Blood 110:54-8. 2007
    ..Nonhematologic adverse events were mild to moderate. (90)Y-ibritumomab is active in patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL) and its further evaluation in phase 3 studies is ongoing...
  19. doi The biphasic transmittance waveform: an early marker of sepsis in patients with neutropenia
    Nazia Hussain
    Addenbrookes Hospital Haematology, Box 234, Cambridge, Cambs CB2 0QQ, United Kingdom
    Thromb Haemost 100:146-8. 2008
    ..It may also provide a useful marker to monitor the effects of treatment...
  20. ncbi Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint
    Robert Marcus
    Department of Medicine, Stanford University School of Medicine, and The Musculoskeletal Research Laboratory, Geriatric Research, Education, and Clinical Center, Veterans Affairs Medical Center, Palo Alto, California 94304, USA
    Endocr Rev 23:16-37. 2002
    ..Consideration of these results from clinical trials can contribute to clinical judgment in selecting the best treatment option for postmenopausal osteoporosis...